Muscle-invasive Urothelial Carcinoma research hub

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

This study is looking at a new treatment for a type of bladder cancer called muscle-invasive urothelial carcinoma (MIUC). It combines an experimental medicine, autogene cevumeran, with an existing drug, nivolumab, to see if this combination works better and is safe compared to nivolumab alone.